Baricitinib Shows Positive Results for SLE in Phase 2 Study

June 19, 2018 Once-daily oral baricitinib 4 mg was associated with significant clinical improvements compared with placebo in patients with systemic lupus erythematosus (SLE) receiving standard background therapy, according to data presented at the European League Against Rheumatism (EULAR) Congress held in Amsterdam, June 13 to 16, 2018…. A significantly greater percentage of patients in the […] Read More